1. A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first‐line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin
   Robert Jones et al, 2020, BJU International CrossRef
2. Preventive Effects of NSAIDs, NO-NSAIDs, and NSAIDs Plus Difluoromethylornithine in a Chemically Induced Urinary Bladder Cancer Model
   Holly L. Nicastro et al, 2014, Cancer Prevention Research CrossRef
3. RNA-Binding Proteins in Bladder Cancer
   Yuanhui Gao et al, 2023, Cancers CrossRef
4. Naproxen Induces Cell-Cycle Arrest and Apoptosis in Human Urinary Bladder Cancer Cell Lines and Chemically Induced Cancers by Targeting PI3K
   Mi-Sung Kim et al, 2014, Cancer Prevention Research CrossRef
5. Suppressive Effect of Matrine on Tumor Invasion in N-Butyl-N-(4-Hydroxybutyl)Nitrosamine-Induced Urinary Bladder Carcinogenesis
   Hua Gao et al, 2014, Chemotherapy CrossRef
6. Prevention of Chemically Induced Urinary Bladder Cancers by Naproxen: Protocols to Reduce Gastric Toxicity in Humans Do Not Alter Preventive Efficacy
   Ronald A. Lubet et al, 2015, Cancer Prevention Research CrossRef
7. Lung cancer chemoprevention: difficulties, promise and potential agents?
   Konstantine Dragnev et al, 2013, Expert Opinion on Investigational Drugs CrossRef
8. Pathway Analysis for Drug Repositioning Based on Public Database Mining
   Yongmei Pan et al, 2014, Journal of Chemical Information and Modeling CrossRef
9. Efficacy of EGFR Inhibitors and NSAIDs Against Basal Bladder Cancers in a Rat Model: Daily vs. Weekly Dosing, Combining EGFR Inhibitors with Naproxen, and Effects on RNA Expression
   Ronald A. Lubet et al, 2021, Bladder Cancer CrossRef
10. Molecular Biology of Urothelial Cancer
    Sounak Gupta et al, 2015, Urological Oncology CrossRef